

Edgar Filing: BioAmber Inc. - Form SC 13G

BioAmber Inc.  
Form SC 13G  
February 13, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

BioAmber Inc.  
(Name of Issuer)

Common  
(Title of Class of Securities)

09072Q106  
(CUSIP Number)

December 31, 2016  
Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this  
Schedule is filed:

X Rule 13d-1(b)  
? Rule 13d-1(c)  
? Rule 13d-1(d)

The information required in the remainder of this cover page shall not  
be deemed to be "filed" for the purpose of Section 18 of the Securities  
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities  
of that section of the Act but shall be subject to all other provisions  
of the Act (however, see the Notes).

CUSIP NO. 09072Q106

1  
Name of reporting person  
S.S. or I.R.S. Identification No. of Above Person

CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.

2  
Check the appropriate box if a member of a group  
(a)

Edgar Filing: BioAmber Inc. - Form SC 13G

(b)  
?

3  
SEC USE ONLY  
4  
Citizenship or place of organization  
  
Vancouver, British Columbia, Canada

5  
Sole Voting Power  
Number of Shares

2,224,199  
Beneficially

6  
Shared Voting Power  
owned

by each reporting

7  
Sole Dispositive Power  
person with

2,224,199

8  
Shared Dispositive Power

9  
Aggregate amount beneficially owned by each reporting person

Connor, Clark & Lunn Investment Management Ltd.  
2,224,199

10  
Check box if the aggregate amount in row (9) excludes certain shares\*

Not Applicable

11  
Percent of Class Represented by amount in Row 9

Connor, Clark & Lunn Investment Management Ltd.  
7.2%

12  
Type of Reporting\*

IA (Investment Adviser)

# Edgar Filing: BioAmber Inc. - Form SC 13G

## SCHEDULE 13G

### Item 1.

(a) BioAmber Inc.  
(b) 1250 Rene Levesque West, Suite 4310  
Montreal, Quebec  
H3B 4W8  
Canada

### Item 2.

(a) CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.  
(b) 2300-1111 West Georgia Street  
Vancouver, BC,  
V6E 4M3  
Canada  
(c) Vancouver, British Columbia, Canada  
(d) Common  
(e) 09072Q106

Item 3. If this statement is filed pursuant to Rule 13d-1(b),  
or 13d-2(h), check whether the person filing is a:  
Investment Adviser in accordance with Rule 13d-1(b) (1) (ii) (E)

### Item 4. Ownership

(a) 2,224,199  
(b) 7.2%  
(c)  
(i) 0  
(ii) 2,224,199  
(iii) 2,224,199  
(iv) 0

Item 5. Ownership of Five Percent or Less of a Class  
Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person  
Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the  
Security being Reported on By the Parent Holding Company  
Not applicable

Item 8. Identification and Classification of Members of the Group  
Not applicable

Item 9. Notice of Dissolution of Group  
Not applicable

### Item 10. Certification

By signing below I certify that, to the best of my knowledge  
and belief, the securities referred to above were acquired in  
the ordinary course of business and were not acquired for  
the purpose of and do not have the effect of changing or  
influencing the control of the issuer of such securities and  
were not acquired in connection with or as a participant

Edgar Filing: BioAmber Inc. - Form SC 13G

in any transaction having such purposes or effect.

Connor, Clark & Lunn Investment Management Ltd. ("Company") is of the view that it and the investment companies and other accounts that it manages are not acting as a "group" for the purposes of section 13(d) under the Act and that it and such investment companies and accounts are not otherwise required to attribute to each other the "beneficial ownership" of securities "beneficially owned" under Rule 13D-3 promulgated under the 1934 Act. Therefore, it is of the view that the shares held by the Company and such investment companies and accounts should not be aggregated for purposes of section 13(d).

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 10, 2017

—

Date

\_\_\_\_\_

Signature

Phil Cotterill, Director —

Name/Title

2

Page